So the key catalyst will be the P3 OA top line readout, potentially around October 2024, and only if the FDA allow us to up the dose to 2mg/kg, making the meeting with the FDA another key catalyst. It is possible regional deals could be struck prior to this readout given that potential partners may want to lock in a deal beforehand or risk having to pay more if the top line readout is a smashing success. PAR should have enough data to secure an upfront payment prior to the top line readout.
Ann: PAR Successful Placement and Fully Underwritten ANREO, page-8
-
- There are more pages in this discussion • 184 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.005(1.92%) |
Mkt cap ! $92.69M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 25.5¢ | $261.4K | 990.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9999 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 9445 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |